The company will stop two trials testing its blockbuster therapy Vyvgart in thyroid eye disease after treatment was judged to ...

Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple ...

The company intends to file a U.S. application in the first half of 2026 following positive study results in a condition ...

Discover why refining COAs is essential to capturing subtle, meaningful patient change—and how teams can close the ...

The deal revolves around a drug Sobi claimed could become the “therapy of choice” for people whose gout symptoms persist ...